Skip to main content
Premium Trial:

Request an Annual Quote

Perlegen, Using Affy Arrays, to Assay SNPs for Merck ...

NEW YORK, Oct. 4 (GenomeWeb News) - Perlegen will provide genotyping services to Merck to find DNA variations with relevance to drug discovery, the company said today.


Under the agreement, Perlegen scientists will assay up to 675,000 SNPs in more than 1,000 DNA samples from individuals "with important clinical characteristics" provided by Merck.


Perlegen will use Affymetrix microarrays, including the GeneChip Human Mapping 500K array set. Merck will integrate the results with in-house data from molecular profiling of tissue samples.


The companies did not disclose the terms of the agreement.

The Scan

Review of Approval Process

Stat News reports the Department for Health and Human Services' Office of the Inspector General is to investigate FDA's approval of Biogen's Alzheimer's disease drug.

Not Quite Right

A new analysis has found hundreds of studies with incorrect nucleotide sequences reported in their methods, according to Nature News.

CRISPR and mRNA Together

Time magazine reports on the use of mRNA to deliver CRISPR machinery.

Nature Papers Present Smartphone Platform for DNA Diagnosis of Malaria, Mouse Lines for Epigenomic Editing

In Nature this week: a low-cost tool to detect infectious diseases like malaria, and more.